Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GalenicaGLLNY 84 EV-to-EBITDA is 7.01 as of Aug. 22, 2026, which is 46% below its 10-year median of 12.93. GuruFocus rates GLLNY with a GF Score™ of 84/100. The stock has 1 warning sign investors should review. Among 98 Medical Distribution companies, Galenica ranks worse than 67.35% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Galenica's enterprise value is $3,115.00 Mil.
Galenica's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $444.64 Mil. Therefore, Galenica's EV-to-EBITDA for today is 7.01.
The historical rank and industry rank for Galenica's EV-to-EBITDA or its related term are showing as below:
GLLNY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.31 Med: 12.93 Max: 18.74
Current: 11.93
During the past 13 years, the highest EV-to-EBITDA of Galenica was 18.74. The lowest was 10.31. And the median was 12.93.
GLLNY's EV-to-EBITDA is ranked worse than 67.35% of 98
companies
in the Medical Distribution industry
Industry Median: 8.405
vs GLLNY: 11.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Galenica's share price for today is $0.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galenica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Galenica's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Galenica's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galenica EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Galenica's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Galenica's EV-to-EBITDA falls into.
Galenica's current Enterprise Value is $3,115.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galenica's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $444.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galenica (GLLNY) has a EV-to-EBITDA of 7.01 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Galenica. This is 46% below median its historical median of 12.93. Over the past decade, Galenica's EV-to-EBITDA has ranged from 10.31 to 18.74. According to the industry distribution chart, Galenica ranks #66 out of 98 companies in the Medical Distribution industry, placing it in the top 67.3%.
Is Galenica's EV-to-EBITDA too high?
Galenica's current EV-to-EBITDA of 7.01 is 46% below median its 10-year median of 12.93. Over the past 10 years, this metric has ranged from a low of 10.31 to a high of 18.74. The Medical Distribution industry median EV-to-EBITDA is 8.41. Galenica's value of 7.01 is 16.6% below this industry median. Based on the distribution chart, Galenica ranks #66 out of 98 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Galenica has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Galenica's EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Galenica ranks #66 out of 98 companies for EV-to-EBITDA. This places Galenica in the lower half of its industry. The industry median EV-to-EBITDA is 8.41. Galenica's value of 7.01 is 16.6% below this benchmark. Historically, Galenica's own EV-to-EBITDA has ranged from 10.31 to 18.74 over the past decade. While the company's 10-year median is 12.93 vs. the industry median of 8.41, Galenica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.41, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galenica's current EV-to-EBITDA of 7.01 is 16.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Galenica. For the Medical Distribution industry, the median EV-to-EBITDA is 8.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galenica's current EV-to-EBITDA is 7.01, which is 46% below median its own 10-year median of 12.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galenica stock overvalued right now?
Galenica (GLLNY) has a current EV-to-EBITDA of 7.01. The current EV-to-EBITDA is 7.01, which is 46% below median its 10-year median of 12.93 and 16.6% below the Medical Distribution industry median of 8.41. Galenica's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Galenica (GLLNY), the current EV-to-EBITDA is 7.01 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galenica Ltd is an integrated healthcare service provider in Switzerland. The business is operated from two segments Products & Care and Logistics & IT. The Products & Care segment comprises the Retail business area with offerings for patients and end customers and the Professionals business area with offerings for business customers and partners in the healthcare sector. The Logistics & IT segment comprises the two sectors Wholesale and Logistics & IT Services. These provide services for all those involved in the healthcare sector - pharmacies, drugstores, doctors, hospitals and care homes, partners, and suppliers. Geographically, it operates in Switzerland and Other Countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLLNY has been successfully added to your 
